UY27680A1 - B3 RECEIVER AGONISTS - ANDRENÉRGICOS. - Google Patents

B3 RECEIVER AGONISTS - ANDRENÉRGICOS.

Info

Publication number
UY27680A1
UY27680A1 UY27680A UY27680A UY27680A1 UY 27680 A1 UY27680 A1 UY 27680A1 UY 27680 A UY27680 A UY 27680A UY 27680 A UY27680 A UY 27680A UY 27680 A1 UY27680 A1 UY 27680A1
Authority
UY
Uruguay
Prior art keywords
andrenérgicos
agonists
adrenergic receptor
receiver agonists
receiver
Prior art date
Application number
UY27680A
Other languages
Spanish (es)
Inventor
Jennifer A Lafontaine
Bradley P Morgan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27680A1 publication Critical patent/UY27680A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona agonistas del receptor b3-adrenérgico de fórmula estructural (I) , así como formulaciones farmacéuticas de los mismos, métodos para tratar enfermedades, trastornos y/o afecciones mediados por el receptor B3- adrenérgico utilizando dichos compuestos.The present invention provides b3-adrenergic receptor agonists of structural formula (I), as well as pharmaceutical formulations thereof, methods for treating diseases, disorders and / or conditions mediated by the B3-adrenergic receptor using said compounds.

UY27680A 2002-02-27 2003-02-25 B3 RECEIVER AGONISTS - ANDRENÉRGICOS. UY27680A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
UY27680A1 true UY27680A1 (en) 2003-10-31

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27680A UY27680A1 (en) 2002-02-27 2003-02-25 B3 RECEIVER AGONISTS - ANDRENÉRGICOS.

Country Status (13)

Country Link
EP (1) EP1485379A1 (en)
JP (1) JP2005518448A (en)
AU (1) AU2003248356A1 (en)
BR (1) BR0308070A (en)
CA (1) CA2476316A1 (en)
DO (1) DOP2003000587A (en)
GT (1) GT200300043A (en)
MX (1) MXPA04007127A (en)
PA (1) PA8567701A1 (en)
PE (1) PE20030943A1 (en)
TW (1) TW200408637A (en)
UY (1) UY27680A1 (en)
WO (1) WO2003072572A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
CN100582088C (en) * 2003-12-23 2010-01-20 安斯泰来制药有限公司 Aminoalcohol derivatives
DE102004021779A1 (en) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, process for their preparation and their use as medicines
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
JP6088535B2 (en) 2011-10-27 2017-03-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Process for producing beta 3 agonists and intermediates
SI2968269T1 (en) 2013-03-15 2019-12-31 Merck Sharp & Dohme Corp. Process for preparing beta 3 agonists and intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
DE69527779T2 (en) * 1994-04-08 2003-03-27 Sumitomo Chemical Co., Ltd. ETHER CONNECTIONS, THEIR USE AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
MX9708621A (en) * 1995-05-10 1998-02-28 Pfizer 'beta'-ADRENERGIC AGONISTS.
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
MXPA03003455A (en) * 2000-10-20 2003-07-14 Pfizer Prod Inc Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists.

Also Published As

Publication number Publication date
AU2003248356A1 (en) 2003-09-09
MXPA04007127A (en) 2005-07-05
WO2003072572A1 (en) 2003-09-04
PA8567701A1 (en) 2003-11-12
EP1485379A1 (en) 2004-12-15
PE20030943A1 (en) 2003-11-08
CA2476316A1 (en) 2003-09-04
DOP2003000587A (en) 2003-08-30
JP2005518448A (en) 2005-06-23
WO2003072572A8 (en) 2004-01-29
BR0308070A (en) 2004-12-21
GT200300043A (en) 2003-09-22
TW200408637A (en) 2004-06-01

Similar Documents

Publication Publication Date Title
UY28766A1 (en) ADDITIONAL HETEROPOLYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEIVER
CR20110077A (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
CY1111977T1 (en) PEPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2
CL2011001263A1 (en) Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
DOP2013000267A (en) HYDROXIMETHYL PIRROLIDINS AS AGONISTS OF THE BETA 3 ADRENERAL RECEIVER
ECSP034809A (en) CICLOBUTENO-1,2-DIONAS 3,4-DISUSTITUTED AS LIGANDS OF THE CXC CHEMOCINE RECEIVER
PA8675701A1 (en) NEW DERIVATIVES OF FLUORENE, COMPOSITIONS THAT CONTAIN THEM AND ITS USE
ECSP077985A (en) PROTEIN CINASE INHIBITORS DERIVED FROM PIRROL (2,3-B) PIRIDINE
ECSP055535A (en) DERIVATIVES OF 1-HETEROCICLIALQUIL-3-SULFONILAZAINDOL OR AZAINDOL AS 5-HYDROXITRIPTAMINE-6 LIGANDS
CL2008002793A1 (en) Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
ECSP088511A (en) NEUROPEPTIDO-2 RECEIVER AGONISTS
ECSP11010885A (en) HETEROARILOS SUBSTITUTED
AR054786A1 (en) (6-FLUOR-BENZOL (1,3) DIOXOLIL) -MORFOLIN-4-IL-METANOMAS, CB1 RECEIVER MODULATORS
ECSP055536A (en) DERIVATIVES OF 1-HETEROCICLILALQUIL-3-SULFONILINDOL OR INDAZOL AS LIGANDS OF 5-HYDROXITRIPTAMINE-6
NO20073182L (en) Indazol-carboxamide
PA8663501A1 (en) DERIVATIVES OF INDOL, BENZOTIOFEN, BENZOFURAN AND INDENO CICLOALQUILCONDENSADOS
DOP2006000061A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
ECSP045473A (en) DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND 1-AMINOALQUIL-3-SULFONYLINDAZOL AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS
ATE441646T1 (en) 5-HT4 RECEPTOR AGONIST COMPOUNDS
CR10497A (en) USEFUL PIPERAZINYL DERIVATIVES IN THE TREATMENT OF DISEASES MEDIATED BY THE GPR38 RECEIVER
ATE431824T1 (en) QUINOLINONE-CARBOXAMIDE COMPOUNDS
ECSP034811A (en) DERETADOS HETEROCICLILOXI-, -TIOXI - Y - AMINOBENZAZOLE SUCH AS LIGANDOS 5-HIDROXITRIPTAMINA-6
NI200700032A (en) ARILSULFONYLESTILBEN DERIVATIVES FOR INSOMNIA TREATMENT AND RELATED AFFECTIONS
CY1113759T1 (en) HIGHLY DISTRIBUTED DOPAMINE COMPETITORS 2
CY1113820T1 (en) 4-ALKOXYPYRIDAZINE PRODUCER AS HIGHLY DISTRIBUTED DOPAMINE RECEPTOR COMPONENTS 2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150423